Literature DB >> 1907499

Evaluation on HIV serology and immune-stimulation on patients in Tanzania.

P Hengster1, E Schmutzhard, D Fuchs, J Hofbauer, H Wachter, M P Dierich.   

Abstract

Antibodies against human immunodeficiency virus, other infectious agents and neopterin levels were determined in 253 patients in a rural area of North-West Tanzania. Seroprevalence for HIV was 3.2%. In one case serology was positive for HIV-1 and HIV-2 antibodies and questions whether there was a real double infection or a cross reaction not only concerning core region proteins but also transmembrane protein. The specificity in the diagnosis of HIV-infection is markedly increased with newer serological methods using recombinant peptides but did not improve sensitivity on African sera. Neopterin was determined as a sensitive indirect marker for the activation of T-cells and is therefore correlated with the susceptibility of HIV infection and with progression of disease. High seroprevalence rates for various infectious agents were determined and may explain the high rate of elevated neopterin levels in 80% of the Africans. Neopterin levels were even higher in HIV patients. Viral p24 antigen was found only in two persons, one of whom had no antibodies detectable.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Antibodies--analysis; Biology; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Examinations And Diagnoses; Hiv Infections; Immunity; Immunologic Factors; Laboratory Examinations And Diagnoses; Measurement; Physiology; Prevalence; Research Methodology; Tanzania; Viral Diseases

Mesh:

Substances:

Year:  1991        PMID: 1907499     DOI: 10.1177/095646249100200306

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  1 in total

1.  West African donors have high percentages of activated cytokine producing T cells that are prone to apoptosis.

Authors:  K Kemp; B D Akanmori; L Hviid
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.